Modified Protocol of Nivolumab in Relapsed/Refractory Hodgkin Lymphoma: A Brief Communication of Real World Data
In conclusion, nivolumab shows comparable efficacy and safety even with compromised dosing and schedule of administration of the drug in real world setting.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
More News: Allergy & Immunology | Hypothyroidism | Immunotherapy | India Health | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants